KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $16.6 million.

  • Halozyme Therapeutics' Share-based Compensation rose 4457.34% to $16.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $51.6 million, marking a year-over-year increase of 1885.44%. This contributed to the annual value of $51.6 million for FY2025, which is 1885.44% up from last year.
  • Halozyme Therapeutics' Share-based Compensation amounted to $16.6 million in Q4 2025, which was up 4457.34% from $12.2 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Share-based Compensation peaked at $16.6 million during Q4 2025, and registered a low of $4.7 million during Q1 2022.
  • Moreover, its 5-year median value for Share-based Compensation was $9.4 million (2023), whereas its average is $8.8 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Share-based Compensation crashed by 367.66% in 2022, and later soared by 7075.42% in 2023.
  • Halozyme Therapeutics' Share-based Compensation (Quarter) stood at $5.1 million in 2021, then skyrocketed by 40.91% to $7.2 million in 2022, then surged by 33.79% to $9.7 million in 2023, then increased by 18.61% to $11.5 million in 2024, then surged by 44.57% to $16.6 million in 2025.
  • Its Share-based Compensation was $16.6 million in Q4 2025, compared to $12.2 million in Q3 2025 and $12.2 million in Q2 2025.